Cilgavimab

3 trials JAnti-infectives

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

2 Completed trials

3 Sponsors

8 Countries

Phase III

Phase IV

Phase III: 1 Phase IV: 2

Indications tested

Coronavirus infection 1

Sponsors using this IMP

Amsterdam UMC Stichting 1 AstraZeneca AB 1 National Institute For Infectious Diseases Lazzaro Spallanzani 1

All trials

3 total

Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after t… Pending

2024-514071-17-00 Phase IV 1 country National Institute For Infectious Diseases Lazzaro Spallanzani
TURN-COVID Biobank: The Dutch cohort study for the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents ag… Ended

2024-515263-60-00 Phase IV 1 country Stichting Amsterdam UMC
Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Ended

2024-512554-15-00 Phase III 6 countries AstraZeneca AB

Showing 1–3 of 3 trials

← All drugs A–Z